Unlocking the Future of Therapeutics

Further → more

Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs.

At Mabion we understand how to advance promising biosimilars and novel biotherapeutics to the clinic and from there to patients. Unfortunately, many promising biopharmaceutical innovations spanning novel recombinant protein therapeutics to biosimilars are being held back in the current, limiting funding climate, depriving patients from access to advanced therapies. Yet the urgency to close gaps in unmet patient care has never been greater.

That is why we are launching the “Unlocking the Future of Therapeutics” competition a unique opportunity to support and accelerate biologics development and scale up for an oncology-targeted therapeutic.

We are offering €500,000 credit in development services to support an exceptional therapeutic project. This can be a novel therapeutic, but might also be a biosimilar drug which expands patients access to lifesaving care.

We have partnered with respected academic experts focused on cancer research to select the most promising candidate.

Nothing in life is to be feared; it is only to be understood.

Let’s grow together!

Let’s close the gap between scientific potential and patient outcomes. Apply now to accelerate your vision!

Welcome to the Competition – Entry Form

The upper limit on the total size of an attached file to an e-mail message is 50 MB. Don’t worry, our BD specialists will take care of you. With larger files, send them straight to bd@mabion.eu

* These fields must be completed.

Meet the Expert Jury

Gestur Viðarsson, Prof.

Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences

Gestur Viðarsson, Prof.

Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences

Leading international expert in immunoglobulin-based biotherapeutics. His main research interests are antibody engineering, molecular biology and immunology. His goal is to understand antibody mediated functions in the broadest term.

Tadeusz Pietrucha, Prof.

Head of the Medical Biotechnology Department at Medical University of Łódź

Tadeusz Pietrucha, Prof.

Head of the Medical Biotechnology Department at Medical University of Łódź

Polish biotechnologist and molecular biologist, founder of the Polish Biotechnology Society, Bio-Forum Łódź and godfather of several Polish biotechnology companies, member of the General Council for Higher Education, Science and Innovation to the President of Poland.

Alicja Santos, PhD

Chief Executive Officer of Polonium Foundation

Alicja Santos, PhD

Chief Executive Officer of Polonium Foundation

Accomplished healthcare innovation leader with nearly two decades of product developemnt and strategy advisory experience spanning cancer, cardiomyopathies and infectious diseases research. Operating on the interface of science, entrepreneurship and business; practicing compassionate leadership across academic, startup, VCs and Fortune 500 environments.

Julita Balcerek,
PhD, MBA, IPMA C

Chief Operating Officer of Mabion

Julita Balcerek, PhD, MBA, IPMA C

Chief Operating Officer of Mabion

In charge of coordinating the Company’s development, manufacturing, investment, and maintenance as well as qualification efforts. Responsible for creation and implementation of new process technologies and development of analytics characterizing biological products and processes. Oversees activities related to purchasing, warehousing, transportation and investment processes.

Further is closer. The breakthrough you need is closer than you think.